Combined metabolic activators accelerates recovery in mild-to-moderate COVID-19
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/8412/Olmuscelik-Oktay-2021.pdf.jpg?sequence=4&isAllowed=y)
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Tarih
2021Yazar
Altay, ÖzlemArif, Muhammad
Li, Xiangyu
Yang, Hong
Aydın, Mehtap
Alkurt, Gizem
Kim, Woonghee
Akyol, Doğukan
Zhang, Cheng
Dinler Doğanay, Gizem
Türkez, Hasan
Shoaie, Saeed
Nielsen, Jens
Boren, Jan
Olmuşçelik, Oktay
Doğanay, Levent
Uhlen, Mathias
Mardinoğlu, Adil
Üst veri
Tüm öğe kaydını gösterKünye
Altay, Ö., Arif, M., Li, X., Yang, H., Aydın, M., Alkurt, G. ... Mardinoğlu, A. (2021). Combined metabolic activators accelerates recovery in mild-to-moderate COVID-19. Advanced Science, 8(17). https://dx.doi.org/10.1002/advs.202101222Özet
COVID-19 is associated with mitochondrial dysfunction and metabolic abnormalities, including the deficiencies in nicotinamide adenine dinucleotide (NAD(+)) and glutathione metabolism. Here it is investigated if administration of a mixture of combined metabolic activators (CMAs) consisting of glutathione and NAD+ precursors can restore metabolic function and thus aid the recovery of COVID-19 patients. CMAs include l-serine, N-acetyl-l-cysteine, nicotinamide riboside, and l-carnitine tartrate, salt form of l-carnitine. Placebo-controlled, open-label phase 2 study and double-blinded phase 3 clinical trials are conducted to investigate the time of symptom-free recovery on ambulatory patients using CMAs. The results of both studies show that the time to complete recovery is significantly shorter in the CMA group (6.6 vs 9.3 d) in phase 2 and (5.7 vs 9.2 d) in phase 3 trials compared to placebo group. A comprehensive analysis of the plasma metabolome and proteome reveals major metabolic changes. Plasma levels of proteins and metabolites associated with inflammation and antioxidant metabolism are significantly improved in patients treated with CMAs as compared to placebo. The results show that treating patients infected with COVID-19 with CMAs lead to a more rapid symptom-free recovery, suggesting a role for such a therapeutic regime in the treatment of infections leading to respiratory problems.
WoS Q Kategorisi
Q1Scopus Q Kategorisi
Q1Kaynak
Advanced ScienceCilt
8Sayı
17Koleksiyonlar
- Makale Koleksiyonu [3790]
- PubMed İndeksli Yayınlar Koleksiyonu [4251]
- Scopus İndeksli Yayınlar Koleksiyonu [6601]
- WoS İndeksli Yayınlar Koleksiyonu [6677]